Pharma Reports

Market Scope uses a multi-source methodology when preparing our annual and quarterly reports. We incorporate surgeon surveys, our extensive database of physicians and surgery centers, disease models, clinical studies, financial reports, and more. Our wide-ranging knowledge of products and technology and our comprehensive network of industry contacts also contribute to our coverage on the ophthalmic industry.

2024 Retinal Pharmaceuticals Market Report: GA and Other Nonexudative Diseases, October, 2024

The “2024 Retinal Pharmaceuticals Market Report: GA and Other Nonexudative Diseases” analyzes the market for complement inhibitors, gene therapies, antioxidants, sustained-release devices, and other treatments for geographic atrophy, dry AMD, and additional nonexudative retinal diseases. The report discusses important trends, analyzes key factors for future market success, examines disease prevalence, reviews patient economics and reimbursement, and forecasts growth over the next five years. Product demand is forecast in units and dollars, and market shares are analyzed by product category. Additionally, 19 competitors are profiled, with discussion of their products, strategic market position, background, and outlook.

2024 Retinal Pharmaceuticals Market Report: Wet AMD and Other Exudative Diseases, September, 2024

The “2024 Retinal Pharmaceuticals Market Report: Wet AMD and Other Exudative Diseases” analyzes the market for anti-VEGFs and other drugs for the treatment of exudative retinal diseases. The report discusses important trends, analyzes key factors for future market success, examines the market’s evolution, and forecasts growth over the next five years. Product demand is forecast in units and dollars, and market shares are analyzed by product category. Additionally, 40 competitors are profiled, with discussion of their products, strategic market position, background, and outlook. 

2024 Glaucoma Pharmaceuticals Market Report: Global Analysis for 2023 to 2029, May, 2024

The “2024 Glaucoma Pharmaceuticals Market Report” analyzes the global and regional markets for glaucoma pharmaceuticals, identifying important trends and key factors for future success. The report provides forecasts through 2029 for branded prostaglandins, generic prostaglandins, beta blockers, carbonic anhydrase inhibitors, alpha agonists, fixed combo drugs, NO-donating compounds, and Rho-kinase inhibitors. The report also extensively discusses pipeline products, covering over 30 drug candidates that are currently under development. Additionally, 26 glaucoma pharmaceutical companies are profiled, with discussion of their products, strategic market position, background, and outlook.

2023 US and Western Europe Cataract Pharmaceuticals Market Report, May, 2023

The “2023 US and Western Europe Cataract Pharmaceuticals Market Report” offers an in-depth examination of the current cataract pharmaceuticals market in the United States and Western Europe and forecasts market performance over the next five years. The report analyzes the current market and forecasts units, average sales price, and revenue through 2028 by product category. It analyzes products currently on the market and examines the development pipeline, discusses the popularity of intracameral injections and fixed combination eye drops, and analyzes the roles of brand name medications, generics, and compounded formulations.

Want to Purchase the Full Report?

Register A Corporate Account

A corporate account gives you access to licensed reports and subscriptions, the latest news, a personalized dashboard, and weekly emails with news and data.

Select one or more
Select one or more